Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Aquestive Therapeutics Inc (AQST)

NASDAQ
Currency in USD
4.390
-0.420(-8.73%)
Closed
After Hours
4.449+0.059(+1.344%)
AQST Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
4.3704.800
52 wk Range
1.8406.230
Key Statistics
Edit
Prev. Close
4.81
Open
4.78
Day's Range
4.37-4.8
52 wk Range
1.84-6.23
Volume
2.06M
Average Volume (3m)
1.41M
1-Year Change
101.26%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AQST Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
10.062
Upside
+129.203%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period
Show more

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company’s proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Employees
135

Aquestive Therapeutics Inc SWOT Analysis


Anaphylm's Promise
Explore Aquestive's groundbreaking sublingual film for anaphylaxis treatment, potentially revolutionizing the emergency allergy market
Clinical Milestones
Delve into Anaphylm's promising pharmacokinetic trial results and stability studies, showcasing its potential as a reliable alternative to auto-injectors
Regulatory Journey
Learn about Aquestive's strategic timeline for Anaphylm's NDA submission and potential FDA approval, with key milestones set for 2024-2025
Market Projections
Analysts estimate peak sales of $300-400 million for Anaphylm, with price targets ranging from $9 to $10, reflecting optimism in Aquestive's future
Read full SWOT analysis
AQST Full Pro Research
Institutional-Grade Stock Analysis
Understand how AQST earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Aquestive Therapeutics Inc Earnings Call Summary for Q3/2024

  • Q2 2024 total revenues up 52% to $20.1M, driven by license and royalty revenue; revised 2024 outlook to $57-60M
  • FDA approved Libervant for pediatric use; Anaphylm NDA filing expected December 2024; minimal cash burn projected
  • R&D costs increased to $4.2M; manufacture and supply revenue decreased due to order timing
  • Non-GAAP adjusted EBITDA loss of $20-23M expected for 2024; $5M revenue from Libervant projected for 2025
  • Exploring partnerships for Anaphylm distribution; inbound interest received for commercial partnering or acquisition
Last Updated: 08-08-2024, 03:58 pm
Read Full Transcript

Compare AQST to Peers and Sector

Metrics to compare
AQST
Peers
Sector
Relationship
P/E Ratio
−11.4x−4.8x−0.7x
PEG Ratio
0.11−0.070.00
Price/Book
−8.8x0.4x2.6x
Price / LTM Sales
6.8x1.1x3.2x
Upside (Analyst Target)
107.9%86.3%43.2%
Fair Value Upside
Unlock12.0%6.8%Unlock

Analysts' Recommendations

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.063

(+129.21% Upside)

FAQ

What Is the Aquestive Therapeutics (AQST) Stock Price Today?

The Aquestive Therapeutics stock price today is 4.39.

What Stock Exchange Does Aquestive Therapeutics Trade On?

Aquestive Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Aquestive Therapeutics?

The stock symbol for Aquestive Therapeutics is "AQST."

What Is the Aquestive Therapeutics Market Cap?

As of today, Aquestive Therapeutics market cap is 401.18M.

What is Aquestive Therapeutics Earnings Per Share?

The Aquestive Therapeutics EPS is -0.436.

What Is the Next Aquestive Therapeutics Earnings Date?

Aquestive Therapeutics will release its next earnings report on 10 Mar 2025.

From a Technical Analysis Perspective, Is AQST a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.